Christopher Martoni;Mitchell Lawrence Jones;Satya Prakash
发明人:
Satya Prakash,Mitchell Lawrence Jones,Christopher Martoni
申请号：
US13111105
公开号：
US10660857B2
申请日:
2011.05.19
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The disclosure provides an oral composition for reducing serum cholesterol, serum lipids, body fat, or atherogenic index or for prophylaxis or treatment of atherosclerosis, cardiovascular or cerebrovascular diseases, comprising a highly bsh active bacteria, isolate or supernatant thereof； wherein the highly bsh active bacteria degrades >；50 μmol glycodeoxycholic acid (GDCA)/gram/hour and >；2 μmol taurodeoxycholic acid (TDCA)/gram/hour when measured over 1 hour and 5 hours, respectively, or degrades >；65 μmol GDCA/g/hr and >；7 μmol TDCA/g/hr when measured over 30 minutes.
